Skip to main content

Table 3 Functional Assessment for Pimobendan Treatment Group

From: Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy

  Baseline Post-pimobendan P value
LAFS 2-D1 (mean% ± SD) 28.9 ± 6.3 32 ± 7.1 0.02
LVFS M-mode1 (mean % ± SD) 61.6 ± 9.3 65.1 ± 8.4 0.08
Mitral TDI S’1 (mean m/s ± SD) 0.075 ± 0.015 0.085 ± 0.016 0.02
MAPSE2 [median mm (IQR)] 4.43 (4.0, 5.1) 4.5 (4.3, 4.9) 0.40
Auricular flow1 (mean cm/s ± SD) 78.2 ± 21.53 87 ± 21.60 0.12
TAPSE1 (mean mm ± SD) 8.58 ± 1.35 8.86 ± 1.08 0.30
IVRT1 (mean ms ± SD) 42.67 ± 9.47 40.17 ± 9.58 0.34
LVOT Vmax2 [median m/s (IQR)] 1.91 (1.45, 3.4) 2.63 (1.98, 3.99) 0.007
RVOT Vmax1 (mean m/s ± SD) 1.5 ± 0.51 2.0 ± 0.53 0.003
HR at LVOT Vmax1 (mean bpm ± SD) 191 ± 24 201.4 ± [28] 0.006
HR at RVOT Vmax1 (mean bpm ± SD) 185 ± 25 197 ± 27 0.04
HR at LAFS1 (mean bpm ± SD) 191.9 ± 25.7 198 ± 26.0 0.29
  1. 1Paired T test
  2. 2Wilcoxon matched-pairs signed rank test
  3. LAFS, left atrial fractional shortening; 2-D, 2-dimensional echocardiography; SD, standard deviation; LVFS, left ventricular fractional shortening; TDI, tissue Doppler imaging; MAPSE, mitral annular plane systolic excursion; IQR interquartile range, IVRT, isovolumic relaxation time, LVOT Vmax, left ventricular outflow tract maximal velocity, RVOT Vmax, right ventricular outflow tract maximal velocity
\